A Message from the Office of National Drug Control Policy Regarding X Waiver
On Jan. 14, 2021, HHS announced forthcoming Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. Unfortunately, the announcement was made prematurely. Therefore, the Guidelines previously announced cannot be issued at this time. However, HHS and ONDCP are committed to working with interagency partners to examine ways to increase access to buprenorphine, reduce overdose rates and save lives.
If you need to reach the Office of National Drug Control, the Office of External and Legislative Affairs can be reached at [email protected].